Insulinotropic hormones and uses thereof
First Claim
Patent Images
1. A method for enhancing the expression of insulin in a pancreatic β
- -type islet cell, said method comprisingproviding to a mammalian pancreatic β
-type islet cell an effective amount of an insulinotropic molecule selected from the group consisting of;
(A) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; and
(B) a derivative of said peptide (A), wherein said derivative is selected from the group consisting of;
(1) a pharmaceutically acceptable acid addition salt of said peptide;
(2) a pharmaceutically acceptable carboxylate salt of said peptide;
(3) a pharmaceutically acceptable lower alkyl ester of said peptide; and
(4) a pharmaceutically acceptable amide of said peptide;
wherein said molecule is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide-1(1-36) (GLP-1(1-36)), or glucagon-like peptide-1(1-37) (GLP-1(1-37)).
1 Assignment
0 Petitions
Accused Products
Abstract
Derivatives of glucagon-like peptide I (GLP-1) and especially GLP-1(7-36) have been found to have insulinotropic activity. The invention pertains to the use of GLP-1(7-36) for the treatment of type II diabetes mellitus.
110 Citations
42 Claims
-
1. A method for enhancing the expression of insulin in a pancreatic β
- -type islet cell, said method comprising
providing to a mammalian pancreatic β
-type islet cell an effective amount of an insulinotropic molecule selected from the group consisting of;(A) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; and(B) a derivative of said peptide (A), wherein said derivative is selected from the group consisting of; (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and (4) a pharmaceutically acceptable amide of said peptide; wherein said molecule is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide-1(1-36) (GLP-1(1-36)), or glucagon-like peptide-1(1-37) (GLP-1(1-37)). - View Dependent Claims (2, 5, 6, 7, 8, 9, 10, 11, 12)
- -type islet cell, said method comprising
-
3. A method for stimulating insulin secretion from the pancreas in an individual in a hyperglycemic state, said method comprising
administering to said individual an effective amount of an insulinotropic molecule which is sufficient to stimulate insulin secretion in said individual, wherein said insulinotropic molecule is selected from the group consisting of: -
(A) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly; and(B) a derivative of said peptide (A), wherein said derivative is selected from the group consisting of; (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and (4) a pharmaceutically acceptable amide of said peptide; wherein said molecule is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide GLP-1 (1-36) (GLP-1 (1-36)) or glucagon-like peptide-1(1-37) (GLP-1(1-37)). - View Dependent Claims (4, 35)
-
-
13. A method for enhancing the expression of insulin in a pancreatic β
- -type islet cell, said method comprising
providing to a mammalian pancreatic β
-type islet cell an effective amount of an insulinotropic molecule selected from the group consisting of;(A) a peptide having the amino acid sequence;
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-X, wherein X is selected from the group consisting of (a) Lys, and (b) Lys-Gly, and(B) a derivative of said peptide (A), wherein said derivative is selected from the group consisting of; (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and (4) a pharmaceutically acceptable amide of said peptide; wherein said molecule is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide GLP-1 (1-36) (GLP-1 (1-36)) or glucagon-like peptide-1(1-37) (GLP-1(1-37)). - View Dependent Claims (14, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
- -type islet cell, said method comprising
-
15. A method for stimulating insulin secretion from the pancreas in an individual in a hyperglycemic state, said method comprising
administering to said individual an effective amount of an insulinotropic molecule which is sufficient to stimulate insulin secretion in said individual, wherein said insulinotropic molecule is selected from the group consisting of: - His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-X, wherein X is selected from the group consisting of (a) Lys, and (b) Lys-Gly,
(A) a peptide having the amino acid sequence; and (B) a derivative of said peptide (A), wherein said derivative is selected from the group consisting of; (1) a pharmaceutically acceptable acid addition salt of said peptide; (2) a pharmaceutically acceptable carboxylate salt of said peptide; (3) a pharmaceutically acceptable lower aklyl ester of said peptide; and (4) a pharmaceutically acceptable amide of said peptide, wherein said molecule is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide GLP-1 (1-36) (GLP-1 (1-36)) or glucagon-like peptide-1(1-37) (GLP-1(1-37)). - View Dependent Claims (16, 36)
- His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-X, wherein X is selected from the group consisting of (a) Lys, and (b) Lys-Gly,
-
37. A molecule that is a pharmaceutically acceptable amide of a peptide having the amino acid sequence:
- His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly, wherein said molecule is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide GLP-1(1-36) (GLP-1 (1-36)) or glucagon-like peptide-1(1-37) (GLP-1(1-37)).
- View Dependent Claims (38, 42)
-
39. A molecule that is a pharmaceutically acceptable amide of a peptide having the amino acid sequence:
- His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-X wherein X is selected from the group consisting of (a) Lys, and (b) Lys-Gly, wherein said molecule is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide-1(1-36) (GLP-1(1-36)) or glucagon-like peptide-1(1-37) (GLP-1(1-37)).
- View Dependent Claims (40, 41)
Specification